Embarking on a journey through the molecular landscape of neurodegenerative diseases, the scientific community has uncovered a beacon of hope in the form of USP30 inhibitors, a class of compounds poised to redefine therapeutic strategies for conditions characterized by mitochondrial dysfunction. Here, USP30 is linked to neurodegenerative disease.